| ioneer Ltd (INR) ORDINARY FULLY PAID |
Materials |
$338 |
Equity Raising Presentation
|
30 Jan 2026 9:54AM |
$0.210 |
$0.110 |
fallen by
47.62%
|
|
INR - Price-sensitive ASX Announcement
Full Release
Key Points
- Equity raising aims to generate ~US$50.4m.
- Funds will support Rhyolite Ridge Project activities through 2026.
- The project is recognized as a strategic US asset.
- Binding offtakes are in place with major customers.
- US Government provides debt funding support.
- Strategic partnership process to conclude by 1H 2026.
- Equity raising involves issuing new shares to select investors.
- The document discusses potential project risks.
- US loan for the project amounts to $996 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ioneer Ltd (INR) ORDINARY FULLY PAID |
Materials |
$338 |
Ioneer Secures US$50 Million to Advance U.S. Onshoring
|
30 Jan 2026 9:53AM |
$0.210 |
$0.110 |
fallen by
47.62%
|
|
INR - Price-sensitive ASX Announcement
Full Release
Key Points
- Ioneer secures US$50 million to advance U.S. onshoring of critical minerals.
- The placement involves issuing approximately 400 million new shares at A$0.18 each.
- The funds will accelerate the development of the Rhyolite Ridge Project.
- The project is the only permitted, shovel-ready lithium-boron project in the U.S.
- Bell Potter Securities and Canaccord Genuity acted as joint lead managers.
- The placement is a strong endorsement of Ioneer’s strategy for U.S. critical minerals production.
- Proceeds will be used for project readiness, environmental permitting, and other costs.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bluglass Limited (BLG) ORDINARY FULLY PAID |
Information Technology |
$34 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 9:53AM |
$0.255 |
$0.260 |
risen by
1.96%
|
|
BLG - Price-sensitive ASX Announcement
Full Release
Key Points
- Secured $1.05 million Year 3 CLAWS Hub contract extension with U.S. Department of War
- Appointed a refreshed Board to drive commercial growth
- Showcased GaN laser portfolio at SPIE Photonics West
- Net cash outflow from operating activities was $3.6 million
- Cash and cash equivalents at the end of the quarter were $3.2 million
- Focus on cost management and funding opportunities
- Expecting R&D tax incentive refunds in FY26
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fin Resources Limited (FIN) |
Materials |
$15 |
FIN to Commence Maiden Drilling at Cabin Lake Gold Project
|
30 Jan 2026 9:53AM |
$0.013 |
$0.011 |
fallen by
15.38%
|
|
FIN - Price-sensitive ASX Announcement
Full Release
Key Points
- FIN to commence 1,500m maiden drilling at Cabin Lake Gold Project.
- Aurora Geosciences appointed as project manager.
- Preparation involves constructing a winter ice road and setting up camp.
- Drilling focuses on confirming historic results and exploring new targets.
- High-grade historical intercepts indicate significant gold potential.
- Acquisition completion expected soon with due diligence finalized.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cavalier Resources Limited (CVR) ORDINARY FULLY PAID |
Materials |
$23 |
Continuity of Gold Confirmed at Miranda Target
|
30 Jan 2026 9:53AM |
$0.410 |
$0.320 |
fallen by
21.95%
|
|
CVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Five drill holes totaling 398 meters confirmed gold continuity at Miranda Target.
- Significant intercepts include 6m at 1.29g/t gold and 2m at 1.06g/t gold.
- Results indicate continuity of gold mineralization over a 100-meter strike length.
- Completion of a Native Title Agreement supports project progression.
- Revised Pre-Feasibility Study completed in April 2025 shows strong economic potential.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WAM Active Limited (WAA) ORDINARY FULLY PAID |
Financials |
$141 |
Entitlement Offer, Shortfall Offer and Placement
|
30 Jan 2026 9:53AM |
$1.085 |
$0.950 |
fallen by
12.44%
|
|
WAA - Price-sensitive ASX Announcement
Full Release
Key Points
- Entitlement Offer of 2 New Shares for every 3 WAM Active shares at $1.00 per share.
- The offer price is a 7.8% discount to the current share price.
- Total capital raise expected to be approximately $51.4 million.
- New Shares are eligible for fully franked interim dividend of 3.2 cps and a 1.0 cps special dividend.
- Shortfall Offer was oversubscribed and led to a $19.3 million institutional placement.
- The placement is to be conducted at the same offer price as the Entitlement Offer.
- The company aims to grow its assets and increase market liquidity.
- WAM Active's investment portfolio has shown strong performance with significant returns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$129 |
Continuation of Trading Halt
|
30 Jan 2026 9:52AM |
$0.045 |
$0.036 |
fallen by
20%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Continuation of trading halt requested by Actinogen Medical Limited.
- The trading halt is related to a proposed material capital raising.
- The trading halt will remain until an announcement or the start of trading on 2 February 2026.
- Actinogen Medical is developing Xanamem for Alzheimer's Disease.
- Xanamem aims to regulate cortisol levels in the brain.
- Xanamem has shown potential in treating cognitive impairment and depression.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clara Resources Australia Limited (C7A) ORDINARY FULLY PAID |
Materials |
$6 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 9:52AM |
$0.003 |
$0.004 |
risen by
16.67%
|
|
C7A - Price-sensitive ASX Announcement
Full Release
Key Points
- Clara Resources Australia Limited reported a net cash used in operating activities of $511,000 for the quarter.
- The company generated $1,353,000 net cash from financing activities.
- Cash and cash equivalents at the end of the quarter amounted to $1,167,000.
- During the quarter, Clara completed a capital raise of $1.587 million, including an institutional placement and a rights issue.
- The acquisition of the Hodgkinson Basin Gold Project was a significant development, involving 533,333,333 fully paid ordinary shares issued to acquire AU SB Minerals Pty Ltd.
- Payments to related parties amounted to $165,000, mainly for interest and director fees.
- There were no mine production and development activities during the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Energy Transition Minerals Ltd (ETM) ORDINARY FULLY PAID |
Materials |
$189 |
Change of Director's Interest Notice
|
30 Jan 2026 9:52AM |
$0.170 |
$0.086 |
fallen by
49.41%
|
|
| Energy Transition Minerals Ltd (ETM) ORDINARY FULLY PAID |
Materials |
$189 |
Proposed issue of securities - ETM
|
30 Jan 2026 9:52AM |
$0.170 |
$0.086 |
fallen by
49.41%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$129 |
ACW positive XanaMIA Interim Analysis outcome
|
30 Jan 2026 9:51AM |
$0.045 |
$0.036 |
fallen by
20%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive interim analysis recommendation from the DMC for the XanaMIA trial.
- Trial involves 220 patients with mild to moderate Alzheimer's Disease.
- Xanamem is being tested for its ability to slow Alzheimer's progression.
- Open-label extension phase will begin in March 2026.
- Second pivotal trial is planned for 2027 in multiple countries including Australia.
- Xanamem controls elevated cortisol levels in the brain, potentially benefiting Alzheimer's patients.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Energy Transition Minerals Ltd (ETM) ORDINARY FULLY PAID |
Materials |
$189 |
Proposed issue of securities - ETM
|
30 Jan 2026 9:51AM |
$0.170 |
$0.086 |
fallen by
49.41%
|
|
| Energy Transition Minerals Ltd (ETM) ORDINARY FULLY PAID |
Materials |
$189 |
Update on Shenghe Top-Up Right
|
30 Jan 2026 9:51AM |
$0.170 |
$0.086 |
fallen by
49.41%
|
|
ETM - Price-sensitive ASX Announcement
Full Release
Key Points
- ETM updates on the Top-Up Right with Shenghe.
- Shenghe holds a 6.5% stake in ETM.
- ETM considers the strategic relationship with Shenghe has ceased.
- The ASX Waiver is no longer applicable.
- ETM will engage with ASX for confirmation.
- Initial strategic relationship included technical cooperation on the Kvanefjeld Project.
- ETM has diversified into lithium projects in Canada and Spain.
- ETM acquired the Penouta tin-tantalum niobium mine in Spain.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Energy Transition Minerals Ltd (ETM) ORDINARY FULLY PAID |
Materials |
$189 |
Successful A$24.7m Placement
|
30 Jan 2026 9:51AM |
$0.170 |
$0.086 |
fallen by
49.41%
|
|
ETM - Price-sensitive ASX Announcement
Full Release
Key Points
- A$24.7 million raised through a single tranche placement.
- Issuance of 190 million new shares at A$0.13 each.
- Strong support from new and existing international institutional investors.
- Funds to progress the Kvanefjeld Project and US strategy.
- Proceeds also to support potential acquisitions and maintain cash reserves for litigation.
- Placement managed by Canaccord Genuity and Evolution Capital.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medallion Metals Limited (MM8) ORDINARY FULLY PAID |
Materials |
$298 |
s708A Notice
|
30 Jan 2026 9:51AM |
$0.495 |
$0.375 |
fallen by
24.24%
|
|
| Alma Metals Limited (ALM) CHESS DEPOSITARY INTERESTS 1:1 |
Energy |
$27 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 9:51AM |
$0.012 |
$0.012 |
fallen by
0%
|
|
ALM - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of 2025 drill program at Briggs with significant mineralized intersections.
- 620m mineralized section at 0.25% Cu and 30m at 0.90% Cu.
- Commitment to prefeasibility study following Scoping Study.
- $2.1 million raised via Share Purchase Plan.
- Cash and liquid investments total $8.8 million.
- Net cash from operating activities of -$130,000.
- Closing cash balance of $2,630,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomic Eagle Ltd (AEU) ORDINARY FULLY PAID |
Materials |
$152 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 9:50AM |
$0.730 |
$0.400 |
fallen by
45.21%
|
|
AEU - Price-sensitive ASX Announcement
Full Release
Key Points
- AEU re-listed on ASX after merging with Tombador Iron Limited and GoviEx Uranium Inc.
- Completed a $10 million capital raising for exploration and development.
- Phil Hoskins appointed as CEO post-merger.
- Reported $19.2 million cash position after merger and capital raising.
- Received $1.08 million in royalty income from Brazilian project.
- Detailed net cash flows from operating, investing, and financing activities.
- Focus on uranium exploration and development in Africa.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pacific Lime and Cement Limited (PLA) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$222 |
Central Lime Project Construction Update
|
30 Jan 2026 9:50AM |
$0.285 |
$0.260 |
fallen by
8.77%
|
|
| Critica Limited (CRI) ORDINARY FULLY PAID |
Materials |
$72 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jan 2026 9:49AM |
$0.032 |
$0.024 |
fallen by
25%
|
|
CRI - Price-sensitive ASX Announcement
Full Release
Key Points
- Critica delivered a second high-grade mixed rare earth product with 86% TREO.
- Gallium by-product recovery potential confirmed with 63% Ga2O3 leach recovery.
- Ongoing pilot and hydromet programs continue to advance Scoping Study work.
- Secured A$8 million through oversubscribed two-tranche placement.
- Received $1 million R&D tax refund, reinforcing financial position.
- Cash and cash equivalents at the end of the quarter stood at $7.2 million.
- Post-quarter funding raised total cash position to approximately $10 million.
- Payments to related parties amounted to A$87,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Codeifai Limited (CDE) ORDINARY FULLY PAID |
Industrials |
$8 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jan 2026 9:49AM |
$0.010 |
$0.008 |
fallen by
20%
|
|
CDE - Price-sensitive ASX Announcement
Full Release
Key Points
- Codeifai Limited reported $138,000 in customer receipts for Q4 2025.
- Net cash used in operating activities was $456,000 in Q4 2025.
- The company is acquiring the QuantumAI Secure platform for quantum-secure solutions.
- A capital raise of $1.1 million was announced.
- Codeifai aims to expand AI capabilities into geospatial intelligence.
- The company ended the quarter with $995,000 in cash.
- A strategic review of the Material Science Division is ongoing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medallion Metals Limited (MM8) ORDINARY FULLY PAID |
Materials |
$298 |
Application for quotation of securities - MM8
|
30 Jan 2026 9:49AM |
$0.495 |
$0.375 |
fallen by
24.24%
|
|
| Verity Resources Limited (VRL) ORDINARY FULLY PAID |
Materials |
$11 |
Trading Halt
|
30 Jan 2026 9:49AM |
$0.025 |
$0.022 |
fallen by
12%
|
|
VRL - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading in the securities of Verity Resources Limited will be halted at the company's request.
- The trading halt is pending the release of an announcement related to a proposed capital raising.
- The halt will remain until the announcement is made or normal trading resumes on 3 February 2026.
- The company has requested the halt to manage continuous disclosure obligations.
- Verity Resources Limited is not aware of any reasons against the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Antares Metals Limited (AM5) ORDINARY FULLY PAID |
Materials |
$6 |
Quarterly Cashflow Report - December 2025
|
30 Jan 2026 9:48AM |
$0.011 |
$0.007 |
fallen by
36.36%
|
|
AM5 - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash outflow from operating activities: $617,000 for the quarter.
- Net cash used in investing activities: $89,000.
- Proceeds from financing activities: $1,030,000 from equity securities.
- Net cash inflow from financing activities: $957,000.
- Cash and cash equivalents at end of period: $1,050,000.
- Payments for tenements at Quinns and Katanning.
- Two-tranche placement expected to raise further funds.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$29 |
Atomo Secures a Significant Order for HIV Self-Test
|
30 Jan 2026 9:48AM |
$0.038 |
$0.036 |
fallen by
5.26%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Atomo Diagnostics Limited secures a significant order for HIV Self-Tests.
- The order is valued at A$416,000 and will be supplied to an African country.
- The order is funded by the Global Fund.
- This is the second Global Fund order in 2026.
- Atomo considers the revenue from this order to be material.
- Managing Director John Kelly highlighted global demand and future growth plans.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$50 |
Quarterly Activities & Cashflow Report
|
30 Jan 2026 9:48AM |
$0.043 |
$0.045 |
risen by
4.65%
|
|
HMD - Price-sensitive ASX Announcement
Full Release
Key Points
- HeraMED completed agreements with Philips and Lee Health to expand in the US.
- 167,000 maternal measurements recorded on the HeraCARE platform.
- Class IIb approval for HeraBEAT in Australia achieved.
- Operating cash outflow was $690k, the lowest since June 2020.
- A $3.2 million capital raise was announced for future operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
